Drug Information

Drug (ID: DG01785) and It's Reported Resistant Information

• Name: Estradiol
• Synonyms: Estradiol; beta-Estradiol; 17beta-Estradiol; 50-28-2; Oestradiol; Dihydrofolliculin; Estrace; Ovocyclin; Vivelle; progynon; Dihydrotheelin; Dihydroxyestrin; Aquadiol; Diogynets; Gynergon; Gynoestryl; Diogyn; Oestroglandol; Aerodiol; Corpagen; Dimenformon; Estrovite; Femestral; Follicyclin; Ginosedol; Macrodiol; Oestergon; Ovahormon; Ovasterol; Ovastevol; Perlatanol; Primofol; Profoliol; Altrad; Bardiol; Climara; Divigel; Evorel; Femogen; Lamdiol; Syndiol; Vagifem; Dihydromenformon; estradiol-17beta; cis-Estradiol; Estraderm TTS; Estraderm; Estraldine; Estroclim; Trocosone; Estrogel; Menorest; Nordicol; Zumenon; Systen; D-Oestradiol; D-Estradiol; Progynon DH; Climaderm; Compudose; Dermestril; Estrasorb; Ovocycline; Encore; Estring; Menest; Oesclim; Dihydroxyoestrin; SK-Estrogens; Progynon-DH; Gynestrel; Microdiol; Oestrogynal; Ovociclina; Ovocylin; Tradelia; Estroclim 50; Innofem; Macrol; Zerella; 17beta-Oestradiol; Alora; Oestradiol R; Estring vaginal ring; Dihydrofollicular hormone; Trial SAT; Theelin, dihydro-; Elestrin; Fempatch; Gynodiol; Oestrogel; Esclim; Compudose 200; Compudose 365; Profoliol B; 17b-Oestradiol; 17-beta-estradiol; Estradiol-17-beta; Estradot; Estrogen; Gelestra; 3,17-Epidihydroxyestratriene; Zesteem; Dihydroxyesterin; cis-Oestradiol; Estraderm TTS 50; Estrogens, esterified; B-Estradiol; Epiestriol 50; 17beta oestradiol; NSC-9895; 17 beta-Estradiol; Estradiol-17 beta; Evamist; Amnestrogen; Femanest; 17.beta.-Estradiol; Estra-1,3,5(10)-triene-3,17beta-diol; 3,17-Epidihydroxyoestratriene; Sandrena 1; 17b-Estradiol; (17beta)-Estra-1,3,5(10)-triene-3,17-diol; Estraderm (TN); [3H]-estradiol; 17; A-estradiol; 17; A-Oestradiol; Estrogel (TN); Climara (TN); Divigel (TN); Estrace (TN); Estring (TN); Innofem (TN); Vagifem (TN); Vivelle (TN); 17.beta.-Oestradiol; 3,17.beta.-Estradiol; .beta.-Estradiol; (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; .beta.-Oestradiol; [3H]]estradiol; UNII-4TI98Z838E; Estradiol, .beta.-; Estradiol-17.beta.; CHEBI:16469; Estra-1,3,5(10)-triene-3,17-diol (17beta)-; Oestradiol-17.beta.; ESTRADIOL HEMIHYDRATE; Oestra-1,3,5(10)-triene-3,17beta-diol; Estrasorb (TN); 17.beta.-OH-estradiol; 17.beta.-OH-oestradiol; 17beta estradiol (E2); Extrasorb; 17beta-Estra-1,3,5(10)-triene-3,17-diol; Estreva; Estrifam; Femtran; Ginedisc; CHEMBL135; GynPolar; (17beta)-estra-1(10),2,4-triene-3,17-diol; Sandrena Gel; D-3,17.beta.-Estradiol; D-3,17.beta.-Oestradiol; Sisare Gel; Estra-1,3,5(10)-triene-3,17-diol, (17beta)-; Estrofem 2; MLS000069494; 3,17b-Dihydroxyestra-1,3,5(10)-triene; Oestradiolum; Climara Forte; 4TI98Z838E; Oestradiol Berco; Estraderm MX; VIVELLE-DOT; 1,3,5-Estratriene-3,17beta-diol; [3H]E2; Oestradiol-17beta; Estrapak 50; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol; (8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 141290-02-0; Estradiolum [INN]; Estradiolo [DCIT]; NCGC00091544-04; Oestradiol-17-beta; Estradiolum; Estrodiolum; Estradiolo; Femestrol; SMR000059126; Estradiol-3,17beta; DSSTox_CID_573; 17-beta-OH-estradiol; 3,17-beta-Estradiol; 3,17beta-Dihydroxy-1,3,5(10)-estratriene; 3,17beta-Dihydroxyestra-1,3,5(10)-triene; 3,17-beta-Oestradiol; D-3,17beta-Estradiol; E(sub 2); DSSTox_RID_75666; Methyl 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate.; Benzogynestry; DSSTox_GSID_20573; Estropause; Estasorb; [2,4,6,7-3H]-E2; E 2; E2; Destradiol; Minivelle; Yuvvexy; Zesteen; .alpha.-Estradiol; 17-beta-OH-oestradiol; 17 -Estradiol; D-3,17beta-Oestradiol; D-3,17-beta-Estradiol; Estrodiolum [INN-Latin]; NSC-20293; D-3,17-beta-Oestradiol; Activella (Salt/Mix); Estradiol Anhydrous; Combipatch (Salt/Mix); CCRIS 280; component of Menrium; Estradiol-17 alpha; Climara Pro (Salt/Mix); 3,17beta-Estradiol; 3,17-.beta.-Oestradiol; Estraderm TTS 100; HSDB 3589; 3,3,5(10)-triene; SR-01000075866; 17-.BETA.-Estradiol; EINECS 200-023-8; (+)-3,17.beta.-Estradiol; 1,3,5-Estratriene-3,17-beta-diol; oestrodiol; Estradiol [USP:INN:BAN]; 3,17beta-Dihydroxyestra-1,3,5-triene; 3,17beta-Dihydroxyoestra-1,3,5-triene; Elestrim; delta-Estradiol; dihydro-Theelin; 3,17-beta-Dihydroxyoestra-1,3,5-triene; delta-Oestradiol; TX-004HR; MFCD00003693; Estra-1,3,5(10)-triene-3,17-beta-diol; Estradiol complex; Estrogel HBF; Oestra-1,3,5(10)-triene-3,17-beta-diol; 1jgl; 1lhu; 1qkt; 1qku; 3,17-beta-Dihydroxyestra-1,3,5(10)-triene; [3H]estradiol; 1,3,5-Estratriene-3,17.beta.-diol; 3,17-beta-Dihydroxy-1,3,5(10)-oestratriene; CAS-50-28-2; 17-beta-Estra-1,3,5(10)-triene-3,17-diol; 17beta-Oestra-1,3,5(10)-triene-3,17-diol; .alpha.-Oestradiol; 17-beta-Oestra-1,3,5(10)-triene-3,17-diol; Estra-1,3,5(10)-triene-3,17-diol; Prestwick_207; 17-beta-oestradiol; 3,17b-Estradiol; Bio-E-Gel; Estradiol 17-beta; Fem7; [3H]-Estrogen; 17 -Estradiol; 3,17.beta.-Dihydroxyestra-1,3,5-triene; 3,17.beta.-Dihydroxyoestra-1,3,5-triene; CMC_11154; 1,3,5,(10)-Estratrien-3,17.beta.-diol; SL-1100; Estra-1,3,5(10)-triene-3,17.beta.-diol; Oestra-1,3,5(10)-triene-3,17.beta.-diol; 17-.beta.-oestradiol; 2j7x; 3,17.beta.-Dihydroxy-1,3,5(10)-estratriene; 3,17.beta.-Dihydroxy-1,3,5(10)-oestratriene; 3,17.beta.-Dihydroxyestra-1,3,5(10)-triene; 3,3,5-triene; [3H]17beta-estradiol; (17 )-Estra-1,3,5(10)-triene-3,17-diol; 17.beta.-Estra-1,3,5(10)-triene-3,17-diol; 17.beta.-Oestra-1,3,5(10)-triene-3,17-diol; Opera_ID_1688; Prestwick0_000441; Prestwick1_000441; Prestwick2_000441; Prestwick3_000441; Spectrum5_002055; 17beta-estradiol (E2); alpha-estradiol (obsolete); beta-Estradiol, >=98%; bmse000642; Epitope ID:136018; (+)-3,17b-Estradiol; E 8875; EC 200-023-8; SCHEMBL8049; (+)-3,17beta-Estradiol; Estradiol (JAN/USP/INN); Tritiated estradiol-17-beta; BIDD:PXR0065; Lopac0_000503; S-21400; BSPBio_000482; BSPBio_001065; KBioGR_000405; KBioGR_002269; KBioSS_000405; KBioSS_002270; Oestradiol-17beta and esters; MLS000758312; MLS001076331; MLS001424022; BIDD:ER0125; Oestradiol-17beta and esters [Steroidal oestrogens]; SPBio_002421; BPBio1_000532; GTPL1012; GTPL1013; DTXSID0020573; Estradiol valerate metabolite e2; NIOSH/KG7030000; BDBM17292; KBio2_000405; KBio2_002269; KBio2_002973; KBio2_004837; KBio2_005541; KBio2_007405; KBio3_000769; KBio3_000770; KBio3_002749; AOB5963; NSC9895; 1a52; 1g50; 2d06; cMAP_000005; Bio1_000403; Bio1_000892; Bio1_001381; Bio2_000363; Bio2_000843; HMS1362E07; HMS1569I04; HMS1792E07; HMS1990E07; HMS2051C17; HMS2090E18; HMS2096I04; HMS2236H04; HMS3261F07; HMS3403E07; HMS3713I04; HMS3884A08; beta-Estradiol, analytical standard; (8S,9S,13S,14S,17S)-13-Methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; BCP08579; HY-B0141; Tox21_111148; Tox21_202057; Tox21_300288; Tox21_500503; 1,5-Estratriene-3,17.beta.-diol; LMST02010001; s1709; WC3011; ZINC13520815; Estradiol-17-beta-6,7-(sup 3)H; [2,4,6,7-3H]-17beta-estradiol; AKOS015896570; CCG-100808; CS-1938; DB00783; LP00503; NC00058; SDCCGSBI-0050487.P002; WC-3011; IDI1_002118; SMP1_000121; NCGC00091544-00; NCGC00091544-01; NCGC00091544-02; NCGC00091544-05; NCGC00091544-06; NCGC00091544-07; NCGC00091544-09; NCGC00091544-10; NCGC00091544-11; NCGC00091544-12; NCGC00091544-13; NCGC00091544-14; NCGC00091544-15; NCGC00091544-16; NCGC00091544-18; NCGC00091544-27; NCGC00179321-01; NCGC00179321-02; NCGC00254177-01; NCGC00259606-01; NCGC00261188-01; 17-E; AC-22346; AS-13729; CPD000059126; H061; Estra-1,3,5(10)-triene-3,17b-diol; Oestra-1,3,5(10)-triene-3,17b-diol; WLN: L E5 B666TTT&J E1 FQ OQ; Estra-1,5(10)-triene-3,17.beta.-diol; Estradiol, meets USP testing specifications; 3,17beta-dihydroxyestra-1,3,5(10)-trien; EU-0100503; KG70300000; Oestra-1,5(10)-triene-3,17.beta.-diol; C00951; D00105; J10189; (17b)-Estra-1,3,5(10)-triene-3,17-diol; 13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol; 17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 17.beta.-Estra-1,5(10)-triene-3,17-diol; 17.beta.-Oestra-1,5(10)-triene-3,17-diol; 003E693; 17-beta-Estradiol 100 microg/mL in Acetonitrile; Q422416; SR-01000721892; 13beta-Methyl-1,3,5(10)-gonatriene-3,17beta-ol; Estra-1,5(10)-triene-3,17-diol (17.beta.)-; Q-201503; SR-01000075866-1; SR-01000075866-4; SR-01000721892-3; BRD-K18910433-001-04-4; BRD-K18910433-001-43-2; estra-1(10),2,4-triene-3,17-diol, (17beta)-; Estra-1,5(10)-triene-3,17-diol, (17.beta.)-; Z1847670481; B8B5AEF5-4957-49EB-A14F-444A8212C482; beta-Estradiol, BioReagent, powder, suitable for cell culture; Estradiol, United States Pharmacopeia (USP) Reference Standard; beta-Estradiol, powder, gamma-irradiated, suitable for cell culture; Estra-1,3,5(10)-triene-3,17-diol, (6,7-(sup 3)H,17-beta)-; (9beta,13alpha,14beta,17alpha)-estra-1,3,5(10)-triene-3,17-diol; Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material; (13S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-beta-diol; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-2,4,6-triene-5,14-diol; 17beta-Estradiol solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material
• Indication:
  In total 1 Indication(s)
  Breast cancer [ICD-11: 2C60]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Ovarian cancer [ICD-11: 2C73]; [1]
• Target: Estrogen receptor (ESR); ESR1_HUMAN; [1]
• IsoSMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O
• InChI: InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1
• InChIKey: VOXZDWNPVJITMN-ZBRFXRBCSA-N
• PubChem CID: 5757
• ChEBI ID: CHEBI:16469
• TTD Drug ID: D08QMX
• VARIDT ID: DR0007
• INTEDE ID: DR00129

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Ovarian cancer [ICD-11: 2C73]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Long non-protein coding RNA (RP11-166P13.3) [1]

• Molecule Alteration: Up-regulation; Expression
• Resistant Disease: Ovarian cancer [ICD-11: 2C73.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: SkOV3 cells; Ovary; Homo sapiens (Human); CVCL_0532
• In Vitro Model: UWB1.289 cells; Ovary; Homo sapiens (Human); CVCL_B079
• In Vitro Model: OVCAR3 cells; Ovary; Homo sapiens (Human); CVCL_0465
• In Vitro Model: CAOV3 cells; Ovary; Homo sapiens (Human); CVCL_0201
• In Vivo Model: Male nude mice xenograft model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR; RNA pull down assay; FISH assay; RIP experiments assay; Knockdown assay
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Long Non-Coding RNA LINC00511 Mediates the Effects of ESR1 on Proliferation and Invasion of Ovarian Cancer Through miR-424-5p and miR-370-5p.

Key Molecule: Long non-protein coding RNA 511 (LINC00511) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Ovarian cancer [ICD-11: 2C73.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: SkOV3 cells; Ovary; Homo sapiens (Human); CVCL_0532
• In Vitro Model: UWB1.289 cells; Ovary; Homo sapiens (Human); CVCL_B079
• In Vitro Model: OVCAR3 cells; Ovary; Homo sapiens (Human); CVCL_0465
• In Vitro Model: CAOV3 cells; Ovary; Homo sapiens (Human); CVCL_0201
• In Vivo Model: Male nude mice xenograft model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR; RNA pull down assay; FISH assay; RIP experiments assay; Knockdown assay
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: Long Non-Coding RNA LINC00511 Mediates the Effects of ESR1 on Proliferation and Invasion of Ovarian Cancer Through miR-424-5p and miR-370-5p.

References

• Ref 1: Long Non-Coding RNA LINC00511 Mediates the Effects of ESR1 on Proliferation and Invasion of Ovarian Cancer Through miR-424-5p and miR-370-5pCancer Manag Res. 2019 Dec 27;11:10807-10819. doi: 10.2147/CMAR.S232140. eCollection 2019.